Amicus Therapeutics Stock News

These five biotech stocks could post life-changing gains for early-bird investors.

Banco Bilbao Vizcaya Argentaria S.A. acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 4th quarter, according to the company in its most recent Form 13F filing with t

Late last night, Elon Musk promised a fan that Tesla “will make ventilators if there is a shortage.” Several hours later, Mayor Bill de Blasio confirmed that there is a national shortage, took him

Companies like Lolli say they cannot keep up with the amount of bitcoin payments they've been asked to process over the past month.

ProShare Advisors LLC cut its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 89,788 shares of the biopharmac

Enphase Energy, Inc. (ENPH), a global energy technology company and the world’s leading supplier of solar microinverters, today announced that the Company has forged an alliance with Amicus Solar Co

Markets just had their most tumultuous week of trading since the financial crisis of 2008. By the end of the week, extraordinary measures had been put in place

Gainers Contura Energy, Inc. (NYSE: CTRA) shares surged 64.7% to close at $4.89 on Friday. Contura is expected to release Q4 results on March 18. Exterran Corporation (NYSE: EXTN...

Bank of Montreal Can boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 314.5% in the fourth quarter, according to the company in its most recent disclosure with the Securiti

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been given a consensus recommendation of “Buy” by the nine ratings firms that are currently covering the company, MarketBeat reports. Two equ

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded down 11.9% during trading on Monday following insider selling activity. The company traded as low as $8.35 and last traded at $8.36, 3,213,353 shares tra

Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.